Cancer Epidemiology Biomarkers & Prevention最新文献

{"title":"Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by Cell-of-Origin.","authors":"Geffen Kleinstern, Dennis P Robinson, Lisa M Rimsza, Melissa C Larson, Rebecca L King, Grzegorz S Nowakowski, Carrie A Thompson, Stephen M Ansell, Matthew J Maurer, Andrew L Feldman, Susan L Slager, Anne J Novak, Thomas M Habermann, James R Cerhan","doi":"10.1158/1055-9965.EPI-24-1610","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1610","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is clinically heterogeneous, and gene expression profiling has identified at least two biologically distinct DLBCL subtypes defined by their cell-of-origin (COO): germinal center B-cell (GCB) and activate B-cell (ABC) or non-GCB. We evaluated a variety of putative DLBCL risk factors for etiologic heterogeneity by COO in a clinic-based study of newly diagnosed DLBCL cases (N=638) and frequency-matched controls (N=2253).</p><p><strong>Methods: </strong>COO was determined on formalin-fixed, paraffin-embedded tumor tissue, with DLBCL classified as GCB (N=283), non-GCB (N=188), or undetermined/missing (N=167; mainly due to lack of tissue). Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>We identified heterogeneity by COO for low socioeconomic status (SES), which was only associated with non-GCB DLBCL (OR=1.88 for low vs average SES, 95%CI 1.08-3.27); alcohol use, which was only associated with GCB DLBCL (OR=0.48 for former drinkers, 95%CI 0.29-0.80; OR=0.47 for current drinkers, 95%CI 0.32-0.71); and borderline heterogeneity for regular use of regular/extra-strength aspirin, which was only associated with non-GCB DLBCL (OR=0.36, 95%CI 0.16-0.85). In contrast, there was no significant heterogeneity by COO for family history, medical history, or other lifestyle factors.</p><p><strong>Conclusions: </strong>While requiring confirmation, most risk factors for DLBCL did not show etiologic heterogeneity by COO, with some notable exceptions including alcohol use, SES, and perhaps regular use of regular/extra-strength aspirin.</p><p><strong>Impact: </strong>Mechanistically, these findings suggest that most of the DLBCL risk factors evaluated here influence lymphomagenesis prior to differentiation into COO subtypes, with selected factors acting later.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National Cancer Institute-funded Cancer Epidemiology Survivor Cohorts: Overview, Progress, and Opportunities.","authors":"Lisa Gallicchio, Andrea N Burnett-Hartman, Kelly K Filipski, Nonniekaye Shelburne, Andrew N Freedman","doi":"10.1158/1055-9965.EPI-24-1750","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1750","url":null,"abstract":"<p><strong>Background: </strong>The goal of this manuscript was to provide an overview of the current National Cancer Institute (NCI)-funded large cancer epidemiology survivor cohorts (CESCs).</p><p><strong>Methods: </strong>Large CESCs were defined as observational cohort studies following at least 1,000 cancer survivors over time and collecting data on survivorship outcomes. CESCs with NCI grant funding on June 1, 2024, were identified in two ways: 1) by identifying grants funded under cancer epidemiology cohort-relevant Notice of Funding Opportunities; and 2) by applying the Research, Condition, and Disease Categorization indexed concepts related to cohorts to the entire NCI grant portfolio in NIH's proprietary Query, View, Report system and reviewing grants identified via this search for inclusion.</p><p><strong>Results: </strong>Thirty active grants supporting large CESCs were identified. Of the 30 CESCs, 36.7% are comprised of survivors of mixed cancer types; the remaining 63.3% are following survivors diagnosed with cancer of a single anatomical type or grouping (e.g. blood cancers). Special populations of focus include adult survivors of pediatric cancers, adolescent and young adult cancer survivors, pediatric cancer survivors, and stem cell transplant survivors. Notable gaps include cohorts following long-term cancer survivors, survivors of less common cancer types, and survivors from understudied populations.</p><p><strong>Conclusions: </strong>CESCs highlighted in this manuscript represent a substantial investment in exploring the multifaceted factors that influence cancer outcomes. These cohorts encompass an increasing diversity of cancer types, treatments, and populations.</p><p><strong>Impact: </strong>CESCs provide valuable insights into clinical and molecular risk factors associated with cancer survivorship outcomes that inform guidelines and interventions.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of inherited genetic variants with multiple primary melanoma.","authors":"David C Gibbs, Brittany M Small, Isidora Autuori, Siok F Leong, Emily Ali, Jessica Kenney, Li Luo, Peter A Kanetsky, Klaus J Busam, Anne E Cust, Hoda Anton-Culver, Richard P Gallagher, Roberto Zanetti, Stefano Rosso, Lidia Sacchetto, Sharon N Edmiston, Kathleen Conway, David W Ollila, Colin B Begg, Marianne Berwick, Irene Orlow, Nancy E Thomas","doi":"10.1158/1055-9965.EPI-24-1442","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1442","url":null,"abstract":"<p><strong>Background: </strong>Recent genome-wide association studies (GWAS) have identified new susceptibility loci for melanoma, but their associations with multiple primary melanoma (MPM) are unclear.</p><p><strong>Methods: </strong>We investigated the associations of 69 single nucleotide polymorphisms (SNPs) in 39 GWAS-identified loci with odds of MPM relative to single primary melanoma (SPM) in the international, population-based Genes, Environment, and Melanoma (GEM) study. Per-minor allele odds ratios (ORs) and 95% confidence intervals (CIs) for individuals with MPM 'cases' (n=1,205) relative to SPM 'controls' (n=2,458) were estimated using multivariable logistic regression, and polygenic risk scores (PRS) were calculated and weighted based on a 2020 GWAS meta-analysis (57 of the 68 independent GWAS SNPs available).</p><p><strong>Results: </strong>Thirteen SNPs in 11 gene regions (PARP1, CYP1B1/RMDN3, TERT, RAPGEF5, TYRP1, MTAP, CDKN2A/CDKN2B, KLF4, TYR, SOX6, ASIP) were statistically significantly associated (P<0.05) with MPM adjusting for age, sex, age-by-sex interaction, and study center. The highest vs. lowest PRS quintile was associated with a 2.81-fold higher odds of MPM (95% CI: 2.10-3.78; P=7.5x10-13); this association was attenuated but remained statistically significant after excluding SNPs individually associated with MPM (OR=1.75, 95% CI: 1.32-2.31).</p><p><strong>Conclusions: </strong>Inherited genetic variants spanning 11 gene regions were independently associated with MPM. Non-significant SNPs were associated with MPM when aggregated into a PRS, indicating their cumulative effect may influence MPM risk despite lacking individual statistical significance in our study population.</p><p><strong>Impact: </strong>Our findings provide additional evidence that these loci are associated with melanoma risk and estimate the magnitude of their genetic effect on subsequent (multiple) primary melanoma risk.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143539429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PATTERNS OF CHANGE IN EMOTIONAL AND FUNCTIONAL WELL-BEING FOLLOWING BREAST CANCER DIAGNOSIS.","authors":"Yumeng Ren, Joanna Maselko, Xianming Tan, Andrew F Olshan, Angela M Stover, Antonia V Bennett, Marc A Emerson, Melissa A Troester","doi":"10.1158/1055-9965.EPI-24-0849","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-0849","url":null,"abstract":"<p><strong>Background: </strong>Understanding emotional and functional well-being (EWB and FWB) change in breast cancer (BC) survivors can facilitate targeted support for unmet needs.</p><p><strong>Methods: </strong>Among 2,767 women with BC in the Carolina Breast Cancer Study Phase 3, we assessed EWB and FWB with the Functional Assessment of Cancer Therapy - Breast (FACT-B) instrument at 5 (baseline), 25, and 84 months post-diagnosis. We identified well-being trajectories using latent class growth analysis, and relative frequency differences (RFDs) with 95% confidence intervals (CIs) were estimated for associations between trajectory group membership and demographic or clinical characteristics.</p><p><strong>Results: </strong>Five trajectory groups were identified for both EWB and FWB. Most participants (~70%) were classified into \"good well-being\" (\"stable high\" or \"stable medium\"). A small percentage (~10%) fell into \"very low baseline\" or \"early decrease\", and the rest were \"stable low\" (~20%). Overall, younger vs. older age was associated with \"stable low\" EWB (25.4% vs. 19.3%; relative frequency difference [RFD] 6.1% [95% CI: 3.0%-9.2%]). Black participants more frequently had \"stable low\" FWB (24.2% vs. 16.6%; RFD 7.6% [95% CI: 4.6%-10.6%]). BC recurrence was strongly associated with \"stable low\" EWB (28.7% vs. 21.3%; RFD 7.3% [95% CI: 2.3%-12.3%]) and FWB (28.7% vs. 19.2%; RFD 8.6% [95% CI: 3.7%-13.5%]). Being unmarried, lower income, having non-private insurance, advanced stage, mastectomy vs. breast conservation surgery, and chemotherapy were also predictors of poor well-being trajectories.</p><p><strong>Conclusions: </strong>Demographics and clinical features are associated with sustained poor well-being after BC.</p><p><strong>Impact: </strong>Improvements in long-term well-being may warrant targeted support.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer screening uptake and Socio-cultural barriers among women in Addis Ababa, Ethiopia: Population based study.","authors":"Ebrahim Mohammed, Girma Taye, Mathewos Aseffa, Adamu Addissie, Ahmedin Jemal","doi":"10.1158/1055-9965.EPI-24-1408","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1408","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is the second leading cause of cancer death among women in Addis Ababa and other parts of Ethiopia. Yet, there are limited age-eligible city-wide data on cervical cancer screening prevalence in Addis Ababa to inform public policy.</p><p><strong>Methods: </strong>A population-based cross-sectional study was conducted among 1881 screening eligible women aged 30-49 years who were selected from 63 enumeration areas in Addis Ababa based on multistage sampling and proportional sample size allocation. Logistic regression was used to identify barriers to screening. All statistical tests were two-sided, p<0.05.</p><p><strong>Result: </strong>30.8% (95%CI: 28.8%, 33.0%) of study participants reported receipt of screening in the past 5 years. Overall, less than half (45.7%) of women reported that they received healthcare provider recommendation for screening, and only 15% of married women reported that they had spousal support for it. In the multivariable adjusted model, the odd of being screened was considerably higher in women with healthcare provider recommendation, with spousal support, and with good cervical cancer screening awareness and knowledge of risk factors for the disease. Factors associated with not seeking screening service included feeling healthy and perception of low risk for cervical cancer.</p><p><strong>Conclusion: </strong>Cervical cancer screening uptake is low in Addis Ababa, and less than half received healthcare provider recommendation. Future studies should identify barriers to provider recommendations.</p><p><strong>Impact: </strong>The findings underscore the need for a coordinated effort to enhance healthcare provider recommendations for cervical cancer screening and to raise awareness about the benefits of screening in the general population.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited Awareness of Alcohol-Related Cancer Risk Factors among Spanish-Preferring Adults in a National U.S. Survey.","authors":"Yi Liao, Andy J King, Benjamin A Lyons, Kimberly A Kaphingst","doi":"10.1158/1055-9965.EPI-24-1354","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1354","url":null,"abstract":"<p><strong>Background: </strong>Alcohol is a modifiable risk factor for several types of cancer, though awareness of this link is often found to be low among the U.S.</p><p><strong>Population: </strong>The current study investigated beliefs about alcohol as a cancer risk factor among Spanish-preferring Americans, specifically for different types of alcoholic beverages (e.g., beer, liquor, and wine).</p><p><strong>Methods: </strong>We analyzed data from a national survey of U.S. adults who prefer speaking Spanish, comparing their awareness of alcohol's link to cancer with the general population and Hispanic respondents in the HINTS 5 Cycle 4 dataset.</p><p><strong>Results: </strong>Awareness among Spanish-speaking adults was lower (wine: 8.2%, beer: 18.3%, liquor: 28.4%) than all HINTS respondents (wine: 20.3%, beer: 24.9%, liquor: 31.2%) and specifically the Hispanic HINTS respondents (wine: 18.3%, beer: 22.4%, liquor: 32.2%). Statistically significant differences were found for wine and beer compared to the general population, and for wine compared to Hispanic respondents. Higher media literacy correlated with increased awareness, particularly for beer, while eHealth literacy showed an inverse relationship. Recent immigrants demonstrated greater awareness than long-term residents. Gender, insurance status, cancer history, and information-seeking behaviors predicted differential awareness.</p><p><strong>Conclusions: </strong>Awareness of the alcohol-cancer link among Spanish-preferring adults in the U.S. is below the national average, with factors such as media literacy, eHealth literacy, demographics, and length of U.S. residency associated with this awareness.</p><p><strong>Impact: </strong>The study underscores the need for culturally adapted health communication strategies to improve knowledge of alcohol as a cancer risk factor among Spanish-preferring Americans.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal Hematopoiesis of Indeterminate Potential as a Predictor of Colorectal Cancer Risk: Insights from the UK Biobank Cohort.","authors":"Yongfeng Liu, Zhihui Xi, Jianlong Zhou, Fa Ling, Yucheng Zhang, Huajie Xie, Jiabin Zheng, Baijin Xia, Huolun Feng, Yong Li","doi":"10.1158/1055-9965.EPI-24-1342","DOIUrl":"10.1158/1055-9965.EPI-24-1342","url":null,"abstract":"<p><strong>Background: </strong>Clonal hematopoiesis of indeterminate potential (CHIP) has been shown to be associated with the occurrence of solid tumors, but its relationship with colorectal cancer still needs to be studied.</p><p><strong>Methods: </strong>We conducted a prospective matched case-control study using data from the UK Biobank, including 5,310 incident colorectal cancer cases and 26,550 controls matched for age, sex, and body mass index.</p><p><strong>Results: </strong>Analysis of the UK Biobank data revealed that the presence of CHIP was associated with an increased risk of colorectal cancer. The odds ratio (OR) for colorectal cancer in the presence of CHIP was 1.20 (P = 0.006). This association remained significant even after excluding participants with a family history of bowel cancer (multivariate OR, 1.19; P = 0.007). Subgroup analyses demonstrated that CHIP independently increased the risk of colorectal cancer in females (multivariate OR, 1.25; P = 0.018) and in individuals older than 60 years (multivariate OR, 1.17; P = 0.046). Gene-specific analyses revealed that mutations in TET2 and ATM were particularly significant in relation to colorectal cancer risk, with an OR of 1.62 (P = 0.002) for TET2 and 2.98 (P < 0.001) for ATM.</p><p><strong>Conclusions: </strong>Our findings indicate that CHIP is associated with an increased risk of colorectal cancer, particularly in individuals more than 60 years of age or in females.</p><p><strong>Impact: </strong>Screening for CHIP in the population may improve the early detection and diagnosis rates of colorectal cancer.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"405-411"},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Clinical Covariates on Serum miRNA Expression among Women without Ovarian Cancer.","authors":"Laura Wollborn, James W Webber, Stephanie Alimena, Sudhanshu Mishra, Chad B Sussman, Cameron E Comrie, Daniel G Packard, Marta Williams, Trinity Russell, Wojciech Fendler, Dipanjan Chowdhury, Kevin M Elias","doi":"10.1158/1055-9965.EPI-23-1355","DOIUrl":"10.1158/1055-9965.EPI-23-1355","url":null,"abstract":"<p><strong>Background: </strong>Serum miRNAs are potential biomarkers for ovarian cancer; however, many factors may influence miRNA expression. To understand potential confounders in miRNA analysis, we examined how sociodemographic factors and comorbidities, including known ovarian cancer risk factors, influence serum miRNA levels in women without ovarian cancer.</p><p><strong>Methods: </strong>Data from 1,576 women from the Mass General Brigham Biobank collected between 2012 and 2019, excluding subjects previously or subsequently diagnosed with ovarian cancer, were examined. Using a focused panel of 179 miRNA probes optimized for serum profiling, miRNA expression was measured by flow cytometry using the Abcam FirePlex assay and correlated with subjects' electronic medical records.</p><p><strong>Results: </strong>The study population broadly reflected the New England population. The median age of subjects was 49 years, 34% were current or prior smokers, 33% were obese (body mass index > 30 kg/m2), 49% were postmenopausal, and 11% had undergone prior bilateral oophorectomy. Significant differences in miRNA expression were observed among ovarian risk factors such as age, obesity, menopause, BRCA1 or BRCA2 germline mutations, or existence of breast cancer in family history. Additionally, miRNA expression was significantly altered by prior bilateral oophorectomy, hypertension, and hypercholesterolemia. Other variables, such as smoking; parity; age at menarche; hormonal replacement therapy; oral contraception; breast, endometrial, or colon cancer; and diabetes, were not associated with significant changes in the panel when corrected for multiple testing.</p><p><strong>Conclusions: </strong>Serum miRNA expression patterns are significantly affected by patient demographics, exposure history, and medical comorbidities.</p><p><strong>Impact: </strong>Understanding confounders in serum miRNA expression is important for refining clinical assays for cancer screening.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"385-393"},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-FDX1 Autoantibody as a Potential Biomarker for Non-Small Cell Lung Cancer Detection.","authors":"Jing Li, Xiaobin Cao, Lulu Zhang, Aichen Liu, Siyu Liu, Fengqi Chen, Yutong Li, Hanke Ma, Wenke Sun, Songyun Ouyang, Liping Dai, Jingjing Liu","doi":"10.1158/1055-9965.EPI-24-1096","DOIUrl":"10.1158/1055-9965.EPI-24-1096","url":null,"abstract":"<p><strong>Background: </strong>Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>A total of 1,155 plasma samples were divided into the verification and validation groups. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using ELISA. Western blotting and immunofluorescence analyses were performed to confirm the ELISA results.</p><p><strong>Results: </strong>Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation groups. The ELISA results were confirmed by Western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an AUC (95% confidence interval) of 0.806 (0.772-0.839) and 0.627 (0.584-0.670), respectively.</p><p><strong>Conclusions: </strong>Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.</p><p><strong>Impact: </strong>These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"439-447"},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential DNA Methylation in the Benign and Cancerous Prostate Tissue of African American and European American Men.","authors":"Meytal Chernoff, Kathryn Demanelis, Marc Gillard, Dayana Delgado, Kevin J Gleason, Meritxell Oliva, Lin Chen, Anthony Williams, Russel Z Szmulewitz, Donald J Vander Griend, Brandon L Pierce","doi":"10.1158/1055-9965.EPI-24-0288","DOIUrl":"10.1158/1055-9965.EPI-24-0288","url":null,"abstract":"<p><strong>Background: </strong>African American (AA) men are at increased risk of prostate cancer compared with European American (EA) men. Biological mechanisms, including epigenetics, likely contribute to this disparity, but prior studies have been limited by sample size, candidate gene approaches, or lack of epigenome-wide DNA methylation (DNAm) data.</p><p><strong>Methods: </strong>To improve our understanding of these mechanisms, we compared DNAm features distinguishing tumor and paired histologically benign tissue from 76 AA and 75 EA patients with prostate cancer. We generated genome-wide array-based DNAm data and conducted differential methylation analyses comparing tumor and benign tissues in each ancestry group. We then examined the predictive ability of our identified sites and differential methylation by ancestry group.</p><p><strong>Results: </strong>We identified 90,747 and 98,929 differentially methylated CpGs in AA and EA, respectively, with 76,400 common to both groups. We identified 6,267 genes with differentially methylated promoters common to both ancestries and 639 and 1,301 genes unique to AA and EA respectively, as well as differentially methylated pathways. Only 10 CpGs were needed to distinguish tumor from benign based on a receiver operating characteristic curve (AUC > 0.9), with differentially methylated CpGs in one ancestry accurately predicting tumor versus benign in the other group. We also identified ancestry-associated CpGs (89 in tumor, 423 in benign).</p><p><strong>Conclusions: </strong>Methylation features distinguishing tumor and benign were similar for EA and AA men; however, subtle differences were identified.</p><p><strong>Impact: </strong>Differences in tumor and ancestry-associated CpGs may reveal differential tumor growth strategies, an important area for future disparities research.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":"428-438"},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}